Author:
Ryan Austin T,Pulukuri Anunay J,Davaritouchaee Maryam,Abbasi Armina,Hendricksen Aaron T,Opp Larissa K,Burt Anthony J,Nielsen Amy E,Mancini Rock J
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference49 articles.
1. Mauger AB, Burke PJ, Somani HH, Friedlos F, Knox RJ. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem. 1994;37:3452–8.
2. Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem. 1998;41:3572–81.
3. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998;58:1195–201.
4. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995;1:1171–7.
5. Sun YL, Patel A, Kumar P, Chen ZS. Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012;31:51–7.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献